2Department of Radiation Oncology, Van Regional Training and Research Hospital, Van-Turkey DOI : 10.5505/tjo.2018.1739 OBJECTIVE
Concurrent chemoradiotherapy is the primary treatment for patients with locally advanced cervical cancer. We evaluated the treatment results and prognostic factors in patients treated with chemoradiation.
METHODS
We retrospectively reviewed the records of 150 patients with locally advanced cervical cancer treated
with curative chemoradiotherapy between 1999 and 2014 at our hospital.
RESULTS
The median follow-up period was 37.5 months (range: 5.6?186 months). All patients received both external
beam radiation therapy (EBRT) and intracavitary brachytherapy. EBRT was delivered with conventional
2-dimensional radiotherapy or 3-dimensional conformal radiotherapy (3DCRT). Eighty-seven
percent of patients received cisplatinum-based chemotherapy during EBRT. Total or nearly total remission
was achieved in 72% of patients. With a median follow-up duration of 37.5 months, 29% of patients
died, 13% of patients had local-regional recurrence, and 25% of patients had distant metastasis. The 2-,
5-, and 10-year overall survival rates were 76%, 62%, and 47%, respectively, and the progression-free
survival rates were 68%, 62%, and 58%, respectively. We evaluated prognostic factors for overall survival
and progression-free survival. The most important prognostic factor was the radiotherapy technique. The
survival curves were estimated by the Kaplan?Meier method, and differences were assessed using the
log-rank test; a p-value<0.05 was considered significant.
CONCLUSION
Chemoradiotherapy is an effective and tolerable treatment method for patients with cervical cancer.
These patients treated with 3DCRT have a better overall survival.